Short answer
Pfizer Inc (PFE) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Cecile Guegan appointed Pfizer CFO and executive vice president, effective November 1, 2026.
Pfizer Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Cecile Guegan appointed Pfizer CFO and executive vice president, effective November 1, 2026
- Permanent appointment follows interim CFO role beginning August 16, 2026, providing leadership continuity
- Guegan brings more than 25 years of pharmaceutical finance experience, including extensive Pfizer operating exposure
- Annual base salary set at $1,300,000
- Target annual cash incentive set at $1,300,000, equal to 100% of base salary
Item EX-99.1 · Exhibit EX-99.1
- Cecile Guegan appointed CFO and Executive Vice President effective November 1, 2026
- Permanent appointment follows interim CFO tenure beginning August 16, 2026, reducing leadership uncertainty
- Over 25 years of pharmaceutical finance experience, including acquisitions, integrations and portfolio forecasting
- Mandate includes disciplined capital allocation and targeted investments intended to support revenue growth later in the decade
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pfizer Inc 8-K filings
Get the next PFE 8-K as it lands
Follow PFE for push alerts, or ask the research agent what this filing means.